A placebo-controlled study investigating the efficacy and safety of the phosphodiesterase type 5 inhibitor UK-369,003 for the treatment of men with lower urinary tract symptoms associated with clinical benign prostatic hyperplasia - Tamimi, N A; Mincik, I; Haughie, S (BJU Int, 2010)
et al.